Pregabalin

Lyrica is a calcium-channel modulator (α2δ subunit) — same family as gabapentin but ~6× more potent and faster-onset. A-tier evidence for neuropathic pain, fibromyalgia, GAD. Also A-tier evidence for genuine abuse liability, rapid tolerance, severe discontinuation syndrome, and a rising body count when combined with opioids (617 deaths in England/Wales 2024). Hard skip for nootropic use — Dylan gets nothing here that L-theanine + propranolol PRN + sleep optimization don't deliver without the dependence trap.

Pregabalin is the second-generation gabapentinoid, designed by Northwestern's Richard Silverman (collaborating with Andrzej Andruszkiewicz) as a structurally GABA-shaped molecule that — despite the name and shape — does not act on GABA receptors, does not affect GABA reuptake, and does not raise GABA levels meaningfully. The "GABA" in the structural design is a red herring that has confused clinicians and patients for 20 years.

The actual target — α2δ subunits of voltage-gated calcium channels:

• Pregabalin binds with high affinity (~6× gabapentin's affinity) to the α2δ-1 and α2δ-2 auxiliary subunits of voltage-gated Ca²⁺ channels in the CNS. The α2δ-1 isoform is the analgesic-relevant target (Field et al. 2006, PubMed 17088553).
• Binding reduces depolarization-induced Ca²⁺ influx into presynaptic terminals.
• Downstream: reduced presynaptic release of glutamate, norepinephrine, and substance P at hyperexcitable synapses (e.g., neuropathic pain pathways, anxiety circuits).
• Net effect: dampens overactive excitatory signaling without globally suppressing neurotransmission. This is why it works for neuropathic pain and anxiety but isn't a sedative-hypnotic in the benzodiazepine sense — though it produces benzo-like subjective effects at higher doses through this same mechanism.

Pharmacokinetics — why it's "better" (and worse) than gabapentin:

• Bioavailability ≥90% across the entire clinical dose range (75-600 mg/day). Linear PK. Contrast: gabapentin uses a saturable L-amino-acid transporter, so doubling the dose yields less than double the exposure.
• Half-life ~6 hours. Steady state in 1-2 days.
• Renal clearance ~73 mL/min, eliminated essentially unchanged via the kidneys. Negligible hepatic metabolism = no CYP interactions, but dose must be reduced for renal impairment (CrCl <60).
• No protein binding, no CYP inhibition/induction. This is the one clean part of its profile.

The Schedule V justification: DEA placed pregabalin into Schedule V on 2005-07-28 (effective immediately after FDA approval 2004-12-31) based on Phase 1 data showing:

• Single 450 mg dose produced subjective ratings of "good drug effect," "high," and "drug liking" comparable to diazepam 30 mg in recreational sedative users.
• 4% of patients in registrational trials (n>5500) reported euphoria as an adverse event — unusually high for a non-controlled candidate.
• Animal self-administration studies confirmed reinforcing properties.

This is the only Schedule V drug in the pure CNS depressant/anxiolytic family in the US — most Schedule V drugs are cough syrups with codeine. Gabapentin, despite the same mechanism, remains unscheduled federally (though several states have scheduled it).